सत्यमेव जयते

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/24/000043

To,

M/s. Eli Lilly and Company (India) Pvt. Ltd.,
Plot No. 92, Sector 32, Institutional Area,
Gurugram, Haryana (India) -122001.

Sir,

With reference to your application No. GCT/CT04/FF/2024/42430 dated 15-03-2024, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, "**A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared with Placebo in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone (TRANSCEND-T2D-1)" Protocol No.: J1I-MC-GZBY Protocol Date 29-NOV-2023 with a total of up-to 170 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

(i) Final carcinogenicity study reports should be submitted to CDSCO.

(ii) Human biological samples i.e. Human blood (whole), Human urine, Human serum, and Human Plasma related to clinical trial shall be permitted to be exported for analysis subject to the clearance by port offices of CDSCO.

(iii) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(iv) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(v) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(vi) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(vii) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(viii) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other

related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(ix) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(x) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(xi) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(xii) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(xiii) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiv) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xv) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xvi) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xvii) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xviii) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xix) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xx) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;

(xxi) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, 2.5.4.20=42d7189b1c0981bb5a263a4a73d025ff4b11b680a91f08773480400a43ee361b, postalCode=110002, st=Delhi, serialNumber=657f5e47d940985d8f03bdc902d0e1fe73cfa12a1a126ea94fa5701124a10013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.10.11 18:28:13 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

FORM CT-06
(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s Eli Lilly And Company, Sector 32, Plot No. 92 Gurgaon Gurgaon (India) -122001 Telephone No.: 1244753000 FAX: 1244753012 E-Mail : IN_REG@LISTS.LILLY.COM** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No.: J1I-MC-GZBY Protocol Date 29-NOV-2023** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in Part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date ________________

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, ou=CENTRAL DRUGS STANDARD CONTROL ORGANISATION, 2.5.4.20=42d7189b1c0981bb5a263a4a73d025ff4b11b680a91f087 73480400a43ee361b, postalCode=110002, st=Delhi, serialNumber=[illegible]a12a1a1 26ea94fa570[illegible]24a19013, cn=RAJEEV SINGH RAGHUVANSHI
Date: 2024.10.11 18:28:20 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	LY3437943
	LY3437943
	LY3437943
	LY3437943
	LY3437943
Therapeutic class:	Antidiabetic
	Antidiabetic
	Antidiabetic
	Antidiabetic
	Antidiabetic
Dosage form:	Solution for injection
	Solution for injection
	Solution for injection
	Solution for injection
	Solution for injection
Composition:	LY3437943 =3.3300 mg/ml In House Specification Active Tris (hydroxymethyl) aminomethane =1.2100 mg/ml U.S.P. Inactive Mannitol =40.0000 mg/ml In House Specification Inactive
	LY3437943 =6.6700 mg/ml In House Specification Active Tris(hydroxymethyl)aminomethane =1.2100 mg/ml U.S.P. Inactive Mannitol =40.0000 mg/ml U.S.P. Inactive
	LY3437943 =10.0000 mg/ml In House Specification Active

	Tris(hydroxymethyl)aminomethane =1.2100 mg/ml U.S.P. Inactive Mannitol =40.0000 mg/ml U.S.P. Inactive
	LY3437943 =15.0000 mg/ml In House Specification Active Tris(hydroxymethyl)aminomethane =1.2100 mg/ml U.S.P. Inactive Mannitol =40.0000 mg/ml U.S.P. Inactive
	LY3437943 =20.0000 mg/ml In House Specification ActiveTris(hydroxymethyl)aminomethane =1.2100 mg/ml U.S.P. Inactive Mannitol =40.0000 mg/ml U.S.P. Inactive
Indications:	Type 2 Diabetes
	Type 2 Diabetes
	Type 2 Diabetes
	Type 2 Diabetes
	Type 2 Diabetes

Annexure:

Details of clinical trial site:

Names and address of clinical trial site	**Ethics committee details**	**Name of investigator**
SCB Medical College,, Cuttack (IEC SCBMCH) Cuttack Orissa - 753007	Institutional Ethics Committee S C B Medical College and Hospital Cuttack, Odisha, India, 753007 ECR/84/Inst/OR/2013/RR-20	Dr Jayanta Panda
Nirmal Hospital Private, Nirmal Hospital Private Ethics Committee, Ring Road, Surat Gujarat - 395002	Nirmal Hospital Ethics Committee Nirmal Hospital Pvt. Ltd.2/1423-8- 6 Sagrampura Ring Road Near Centre Point Surat 395002 Gujarat Surat Surat Gujarat - 395002 India ECR/390/Inst/GJ/2013/RR-19	Dr Piyush H Deasi
Eternal Heart Care Centre & Research Institute, Ethics Committee, Eternal Heart Care Centre & Research Institute, 3A, Jagatpura Road, Jawahar Circle, Jaipur Rajasthan -302020	Eternal Heart Care Centre and Research Institute - Institutional Ethics Committee Eternal Heart Care Centre and Research Ins Pvt Ltd, 3A, Jagatpura Road, Near Jawahar Circle, Jaipur, Rajasthan, India, 302017 ECR/615/Inst/RJ/2014/RR-20	Dr Jugal Bihari Gupta
Brij Medical Centre,, Ethics Committee,Brij Medical Centre, 94-E, Panki (Near Panki Police Station) Kanpur UttarPradesh - 208020	Ethics Committee Brij Medical Centre Brij Medical Center Pvt LtdPanki Panki Kanpur Nagar Kanpur Nagar Uttar Pradesh - 208020 India ECR/642/Inst/UP/2014/RR-20	Dr Brij Mohan

Institute All India Institute of Medical Sciences,, Institute Ethics Committee, AllIndia Institute of Medical Sciences, Department of Pharmacology, 2nd Floor, South Wing, Medical College Complex, Gate No.5, ,Tatibandh, GE Road, Raipur Chhattishgarh - 492099	Institute Ethics Committee, Aiims Raipur Room no. 2103, 2nd Floor South Wing Medical College Complex, Gate No. 5All India Institute of Medical Sciences, Tatibandh, GE Road, Raipur, 492099,Chhattisgarh, India ECR/714/Inst/CT/2015/RR-21	Dr Amritava Ghosh
Gujarat Endocrin Pvt Ltd, Gurukul Metro Road, 518-526 aws-3 Bldg, Opp to Manav Mandir, Besides Gandhi laborinstitute, Near Drive cinema Ahmedabad Gujarat - 380052	Sangini Hospital Ethics Committee Sangini Hospital Santorini Square, B/H Abhishree Complex Opp. Star Bazar Nr Jodhpur Cross Roads Satellite Ahmedabad Ahmedabad Gujarat ECR/147/Inst/GJ/2013/RR-19	Dr Parag Rajnikant Shah
Victoria Hospital, Bangalore Medical College And Research Institute, Room 322, 3rd Floor, OPD Block Fort, K.R. Road, Karnataka, India, Bangalore Karnataka - 560002	Ethics Committee of BMCRI Bangalore Medical College And Research Institute, Fort K R Road Bengaluru Bengaluru (Bangalore) Urban Karnataka - 560002 India ECR/302/Inst/KA/2013/RR-20	Dr Sivaranjani Holigi
Government Medical College Kozhikode, Calicut, Kozhikode Kerala - 673008	Institutional Ethics Committee Govt Medical College Kozhikode 4th Floor, Golden Jubilee Annex Institute of Maternal and Child Health Kozhikode Kozhikode Kerala - 673008 India ECR/395/Inst/KL/2013/RR-20	Dr Chandni R

****